BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23129737)

  • 1. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma.
    Blumenfeld Z; Dann E
    J Clin Oncol; 2013 Oct; 31(29):3721. PubMed ID: 24002509
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Z. Blumenfeld et al.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2013 Oct; 31(29):3722-3. PubMed ID: 24002513
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
    Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
    JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
    Zhang Y; Xiao Z; Wang Y; Luo S; Li X; Li S
    PLoS One; 2013; 8(11):e80444. PubMed ID: 24312222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
    Blumenfeld Z; Avivi I; Linn S; Epelbaum R; Ben-Shahar M; Haim N
    Hum Reprod; 1996 Aug; 11(8):1620-6. PubMed ID: 8921104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
    Del Mastro L; Ceppi M; Poggio F; Bighin C; Peccatori F; Demeestere I; Levaggi A; Giraudi S; Lambertini M; D'Alonzo A; Canavese G; Pronzato P; Bruzzi P
    Cancer Treat Rev; 2014 Jun; 40(5):675-83. PubMed ID: 24360817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma.
    Falorio S; Angrilli F; Fioritoni G
    Leuk Lymphoma; 2008 Jun; 49(6):1087-93. PubMed ID: 18452079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
    Badawy A; Elnashar A; El-Ashry M; Shahat M
    Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
    J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
    Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
    Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian rescue/protection from chemotherapeutic agents.
    Blumenfeld Z
    J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
    Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
    Blumenfeld Z; Zur H; Dann EJ
    Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study.
    Li X; Kang X; Deng Q; Cai J; Wang Z
    Reprod Biol Endocrinol; 2013 Mar; 11():16. PubMed ID: 23452939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fertility after treatment for Hodgkin's disease.
    Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
    Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease.
    Azem F; Samara N; Cohen T; Ben-Yosef D; Almog B; Lessing JB; Goor O; Amit A
    J Assist Reprod Genet; 2008; 25(11-12):535-8. PubMed ID: 19015974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients.
    Nitzschke M; Raddatz J; Bohlmann MK; Stute P; Strowitzki T; von Wolff M
    Arch Gynecol Obstet; 2010 Jul; 282(1):83-8. PubMed ID: 19967405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
    Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.